FDA panel to focus on safety of Novartis gene therapy drug

(Reuters) - The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG's experimental gene therapy drug when it meets to review the leukemia treatment on Wednesday.